Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.

Si Fang James Yarmolinsky Dipender Gill Caroline J Bull Claire Marie Perksnull nullGeorge Davey Smith Tom R Gaunt Tom G Richardson

Published in: PLoS medicine (2023)

Our study supports a strong association between genetically proxied inhibition of PCSK9 and a lower risk of total and early-onset PrCa, potentially through an alternative mechanism other than the on-target effect on LDL-c. Further evidence from clinical studies is needed to confirm this finding as well as the putative mediatory role of Lp(a).

Keyphrases

early onset
prostate cancer
late onset
low density lipoprotein